Teladoc Health Inc

Teladoc Health has a market price of $6.57 and a market cap of $1.19 billion, with a price-to-book ratio of 0.86, indicating that the company is trading below its book value. The company's liquidity position is characterized by $781.08 million in cash and equivalents, but it also carries $994.93 million in long-term debt, resulting in a debt-to-equity ratio of 0.72. The current ratio of 2.77 suggests that the company has sufficient current assets to cover its short-term liabilities. Profitability metrics show a return on equity of -14.46% and a return on assets of -7.01%, indicating that the company is currently unprofitable. The operating income is negative at -$262.96 million, and the net income is also negative at -$200.32 million. These figures suggest that the company is not generating sufficient revenue to cover its operating costs and is experiencing a decline in profitability. Teladoc Health's revenue is concentrated in its core telehealth services, with no significant geographic diversification disclosed in the available data. The company's revenue of $2.53 billion is primarily derived from subscription-based models and service fees, with no major segments or geographic regions highlighted in the financial snapshot. The company's growth trajectory is mixed, with a revenue of $2.53 billion but a negative operating income of -$262.96 million. The capital expenditure of -$157.02 million indicates a reduction in investment in physical assets, which may reflect a strategic shift toward digital infrastructure. The free cash flow of $6.73 million is minimal, suggesting that the company is not generating significant cash from operations to reinvest or return to shareholders. Risk factors include a medium liquidity risk due to the company's negative net cash position after subtracting total debt. The dilution risk is low, with no significant changes in shares outstanding between basic and diluted shares. The company's financial performance and operational challenges may impact its ability to sustain growth and maintain profitability in the near term. Recent events include analyst estimates with a mean price target of $7.05 and a median price target of $6.00, indicating a mixed outlook from the investment community. The mean recommendation of 2.67 suggests a slight bias toward a hold or buy rating, with 20 analysts recommending a hold. These estimates reflect the market's uncertainty about the company's future performance and its ability to turn around its financial position.